Abstract
Canine osteosarcoma (OS) is an aggressive cancer that comprises 85% of canine bone neoplasms, affecting mainly larger breeds such as the Irish wolfhound.
Current treatment options for the disease result in a 1-year survival rate of 45%, with 54% of cases developing metastatic tumours. Successful canine therapy provides translational data supportive for human trialling due to OS similarities. Therefore, the present study aimed to identify a potent curcumin analogue in two canine OS cell lines.